Evidence-based CVD secondary prevention medications (such as anti-platelets, statins, beta-blockers, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin-receptor blockers (ARBs)) in CHD and antiplatelets, statins, and any of the antihypertensive drugs (like beta-blockers, ACE-I or ARBs, calcium channel blockers or diuretics) in stroke (7, 8, 9, 10, 11, 12) is expected to reduce the recurrence of the event or death by 60 to 80% (13, 14). This evidence concerns the gene ACE and Stroke.